Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Accumulated Depreciation (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Accumulated Depreciation for 6 consecutive years, with $17.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Depreciation rose 20.19% year-over-year to $17.5 million, compared with a TTM value of $17.5 million through Dec 2025, up 20.19%, and an annual FY2025 reading of $17.5 million, up 20.19% over the prior year.
  • Accumulated Depreciation was $17.5 million for Q4 2025 at SAB Biotherapeutics, up from $15.3 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $17.5 million in Q4 2025 and bottomed at $3.2 million in Q4 2021.
  • Average Accumulated Depreciation over 5 years is $9.3 million, with a median of $8.1 million recorded in 2022.
  • The sharpest move saw Accumulated Depreciation skyrocketed 94.98% in 2022, then rose 20.19% in 2025.
  • Year by year, Accumulated Depreciation stood at $3.2 million in 2021, then soared by 94.98% to $6.3 million in 2022, then skyrocketed by 57.87% to $9.9 million in 2023, then soared by 47.04% to $14.6 million in 2024, then rose by 20.19% to $17.5 million in 2025.
  • Business Quant data shows Accumulated Depreciation for SABS at $17.5 million in Q4 2025, $15.3 million in Q1 2025, and $14.6 million in Q4 2024.